zoezen schreef:
Biolex Therapeutics of Pittsboro closed on a $30 million Series C financing led by Investor Growth Capital of New York and including two other new investors, JP Morgan Securities and Easton Capital, as well as existing shareholders including Quaker BioVentures, Polaris Venture Partners, Intersouth Partners, Mitsui & Co.
Venture Partners, Johnson & Johnson Development Corporation and Dow Venture Capital. The funds will be used primarily to advance Biolex's lead drug candidate Locteron into phase 3 clinical development in hepatitis C, and to advance the company's other drug candidates.
Hier moet biolex Blijkbaar zijn centjes vandaan halen.
of is JJ de eene uit de Top 10.